- Created on the 29 June, 2017.
Human thrombosis profile ELISA kit is designed for detecting in-vitro quantitative levels of IgG or IgM autoantibodies to phospholipids and beta-2-glycoprotein I (thrombosis-profile) in human plasma and serum. This assay has a minimum analytical sensitivity limit of 1.0 U/ml.
Highly purified human beta-2-glycoprotein I, cardiolipin, phosphatidyl inositol, phosphatidyl serine and phosphatidic acid are bound to individual rows of the microwell plate.
There are a complex group of auto-antibodies that are linked to thrombosis in connective tissue disease and primary anti-phospholipid syndrome. The antibodies are usually present in patients without lupus but instead with myocardial infarction, arterial and venous thrombosis, recurrent abortion, neurological symptoms and strokes in young people. Even though anti-cardiolipin are most commonly measured, it is also widely accepted that only one group that contains anti-phospholipid auto-antibodies with several specificities can be found in these patients. The detection of these antibodies has led to the identification of a new disease entity that has been called anti-phospholipid syndrome (APS). Anti-cardiolipin antibodies which are associated with APS can be used to recognise a serum protein b2-glycoprotein 1 which is also linked with phospholipid. Anti-cardiolipin auto-antibodies have the ability to recognise any combination of IgG, IgM and IgA classes. The following thrombosis profile ELISA kit has the ability to recognise IgG and IgM auto-antibodies which are directed against human beta-2-glycoprotein I and phospholipids. However, it must be noted that the antibody concentrations present do not necessary have to correlate with the severity or extent of thrombosis.
The minimum detection sensitivity level of beta-2-glycoprotein I and phospholipids IgG/IgM autoantibodies (thrombosis-profile) using current human thrombosis profile ELISA kit was 1.0 U/ml. The dynamic range for this assay is 6.3 – 100.0 U/ml.
- Management of recurrent thrombosis in antiphospholipid syndrome. Curr Rheumatol Rep. (2014) 16 (3): 405. Review. Nalli C., et al.
- Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus. (2010) 19 (4): 432-5. Tincani A., et al.
- Prevention of thrombosis in antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. (2016) 2016 (1): 707-713. Review. Lim W.
- Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep. (2011) 13 (1): 59-69. Review. Barbhaiya M. and Erkan D.
- Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies. Expert Opin Drug Metab Toxicol. (2013) 9 (7): 901-9. Review. Donadini M.P., et al.
- Full Name: Thrombosis Profile ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma
- Sensitivity: 1.0 U/ml